Cytokinetics, GlaxoSmithKline deal

GlaxoSmithKline will not exercise its option to license ispinesib and SB-743921 from Cytokinetics under a 2001 deal. GSK said the decision not to license the kinesin spindle protein ( KSP) inhibitors was due to a "shift in portfolio direction." The partners will continue to collaborate on GSK-923295, a small molecule centromere-associated protein E (CENPE) inhibitor in Phase I testing to treat solid tumors, to which Cytokinetics has an option. ...